The FDA has granted Breakthrough Therapy designation for litifilimab for the treatment of cutaneous lupus erythematosus, a chronic autoimmune skin disease.

The FDA has granted breakthrough therapy designation for litifilimab in patients with cutaneous lupus erythematosus, ...

Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous ...

In patients with systemic lupus erythematosus, impaired upper limb function and difficulty performing daily activities are linked to various quality-of-life domains.

Our most recent episode of The Expert Series podcast explores the newly released SLE treatment guidelines and how they might affect patient care.

How would you treat a 30-year-old woman with systemic lupus erythematous (SLE) and lupus nephritis (LN) class 3 with new ...

Dear Dr. Roach: What is lupus, and what does it do to your body? I just had a friend diagnosed with it after many months of tests. — T.S.B. Dear T.S.B.: The term "lupus" generally means systemic lupus ...

The Phase III AMETHYST study is currently assessing litifilimab’s safety and efficacy, with results anticipated in 2027.

In a new study, researchers found people with clinically active systemic lupus erythematosus (SLE) disease on standard of care can attain or achieve low disease activity (LLDAS) and meet the ...

SEN. Bong Go has hailed the approval on third and final reading of Senate Bill (SB) 1513, or the proposed Comprehensive Lupus ...